Trump’s Risk For A Cardiac Event Is Seven Times Hilary Clinton’s Risk
Editor’s note: The following guest post is reprinted with permission from Dr. Anthony Pearson, a cardiologist who is the medical director of the Echocardiography Laboratory and Anticoagulation Clinic...
View ArticleNo, $75 Million Won’t Cure Heart Disease Or Reinvent Science
–Silicon Valley hype and hubris come to cardiology. We may be close to peak hype and hubris in cardiology. This week some of the smartest people on the planet said that $75 million can help find new...
View ArticleSeeking Profit and Investors, Rogue Lab Moves Into Small Hospitals
A controversial new laboratory company specializing in “advanced cardiovascular risk testing” is developing an innovative, highly profitable– and legally dubious– new business model. Details of the...
View ArticleDebaters At Interventional Cardiology Meeting Literally Put The Gloves On
The world’s premiere interventional cardiology meeting now features cardiologists wearing boxing shorts and gloves. The Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC kicked...
View ArticleIs The American Heart Association Trying To Kill Health Reporters?
The answer is no. The AHA is not trying to kill us. But its dietary advice is consistently confusing and occasionally wrong, and health reporters in New Orleans may end up as collateral damage. Just...
View ArticleLunchroom Scandal At The AHA: Day Two Of Buttergate
–After a CardioBrief investigation the American Heart Association changes the lunchroom menu There is no better proof that journalism can change the world– both for the good and the bad– than...
View ArticleTelling People What They Want To Hear: Alt-Med And Donald Trump
Donald Trump won* the election because he told people what they wanted to hear. Alternative medicine is growing in popularity because it tells people what they want to hear. Of course, there’s a big...
View ArticleNovartis Contest Rewards Positive Peer Review Articles About Entresto
(Updated) Despite the fact that it had one of the biggest clinical trial successes in recent years, the Novartis heart failure drug Entresto has been struggling to gain acceptance in the marketplace....
View Article2016: Great Year Or Greatest Year Ever?
Editor’s note: Once again Larry was too depressed to write the 2016 yearly review. (Actually, he’s hiding under his bed.) Veteran healthcare journalist and eternal optimist Candide Corn has again...
View Article